CAMI Health and the Resource Tracking for HIV Prevention Research and Development Working Group published this 2016 analysis of investment through grants in multipurpose prevention technology. Read on for statistics showing increased funding overall, and review research and development progress to date.
Global Investments in Multipurpose Prevention Technology Research and Development
Px Wire January-March 2017, Vol. 10, No. 1
This issue of Px Wire, AVAC’s quarterly update on HIV prevention research, looks ahead at a host of issues we are watching in 2017. Are we confronting “Fast Track” goals with the sober analysis they demand? Will oral PrEP guidelines translate into programs and will programs meet people’s needs? What progress can we expect from studies on the dapivirine vaginal ring, various vaccine candidates or on broadly neutralizing antibodies, which are garnering so much press attention of late? Will global leaders embrace policies that ensure data gaps on key populations will finally be filled?
End-User Research Landscape Mapping & Findings
The HIV Prevention Market Manager undertook an effort to map the landscape of ongoing and planned work on HIV prevention and adolescent girls and young women and other populations in sub-Saharan Africa. This document provides a summary and analysis of the end-user projects and studies underway in order to inform collaborations and identify gaps and next steps in research.
AVAC Introduction to Long-Acting Injectables
A strategy that uses long-acting injectables is being tested now for treatment and prevention. Injected antiretrovirals that are being developed to remain effective for weeks or months could potentially simplify adherence. Our infographic explains the research underway and reviews some of the major questions that research must address.
Px Wire October-December 2016, Vol. 9, No. 4
The theme of this year’s World AIDS Day captures the spirit: Hands Up for HIV Prevention. At AVAC, we’re delighted to see the focus on this critical area of the global response. Our new issue of Px Wire provides specifics on some hot topics for advocacy before, on and after World AIDS Day.
HIV Prevention Research & Development Investments, 2000–2015: Investment priorities to fund innovation in a challenging global health landscape
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2015, reported funding for HIV prevention R&D decreased from US$ 1.25 billion in 2014 to US$1.20 billion. However, overall funding has remained essentially flat for over a decade. While investments towards research for preventive vaccines and female condoms increased from 2014 levels, investments towards microbicides, PrEP, TasP, VMMC and PMTCT declined.
HIV Prevention Research & Development Investments, 2000–2015: Investment priorities to fund innovation in a challenging global health landscape (1-pager)
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2015, reported funding for HIV prevention R&D decreased from US$ 1.25 billion in 2014 to US$1.20 billion. However, overall funding has remained essentially flat for over a decade. While investments towards research for preventive vaccines and female condoms increased from 2014 levels, investments towards microbicides, PrEP, TasP, VMMC and PMTCT declined.
Slow and Steady Won’t Win the Prevention Race
Progress in voluntary medical male circumcision has made significant gains but still fell short of targets—or why VMMC isn’t a global priority and how to make it one. Excerpted from AVAC Report 2016: Big Data, Real People.
PrEP for MSM in Africa: Meeting Summary and Next Steps
Advocates gather in South Africa for the continent’s first PrEP and MSM consultation to chart a path for PrEP access. See the report summary with links to presentations and country plans.
Programs but Not Yet Platforms: The peril and promise of women’s biomedical HIV prevention in 2016
The benefits of PrEP is winning over support from international bodies and an increasing number of national governments. PrEP introduction is advancing on several fronts, but all this momentum has yet to impact some of the people who need it most, in particular, adolescent girls and young women with high risk of acquiring HIV. Check out our up-close look at the issue from AVAC 2016’s Big Data, Real People.